Prolonged Heat Exposure in Cystic Fibrosis Can Lead to Metabolic Alkalosis
In patients with cystic fibrosis, prolonged exposure to heat can lead to chloride-deficient metabolic alkalosis as a result of a loss of electrolytes through sweat.
Obstructive Lung Disease
Brensocatib Receives Breakthrough Therapy Status for Non-CF Bronchiectasis
The FDA has granted Breakthrough Therapy designation to brensocatib for the treatment of adults with non-cystic fibrosis bronchiectasis for reducing exacerbations.
Pancreatic Status Affects Lung Function Decline in Adults With Cystic Fibrosis
In adults with cystic fibrosis, pancreatic status — that is, being pancreatic sufficient vs being pancreatic insufficient — has been shown to have a pronounced effect on the average rate of decline in lung function.
Pravibismane Gets Orphan Drug Status for Pulmonary Infections in Cystic Fibrosis
The FDA has granted Orphan Drug designation to pravibismane suspension for inhalation (BisEDT antimicrobial suspension; Microbion) for the management of pulmonary infections in patients with cystic fibrosis.
Tobacco Smoke Exposure Limits Benefits of CFTR Modulators in Cystic Fibrosis
Tobacco smoke exposure inhibited the therapeutic benefit of the cystic fibrosis transmembrane conductance regulator modulators in pediatric patients.
Lumacaftor-Ivacaftor May Improve Glucose Tolerance in Cystic Fibrosis
Patients with cystic fibrosis who were treated for 1 year with a combination of lumacaftor and ivacaftor saw improvements in glucose tolerance abnormalities
Inhaled Messenger RNA Treatment Fast-Tracked for Cystic Fibrosis
The FDA has granted Fast Track designation to MRT5005, an inhaled messenger RNA (mRNA) therapeutic being investigated for the treatment of cystic fibrosis.
Ultrasound May Identify Children at Risk for Cystic Fibrosis Liver Disease
A heterogeneous liver pattern could indicate a higher risk for advanced cystic fibrosis liver disease.
Investigational Antibiotic Receives Orphan Drug Status for CF Pulmonary Exacerbations
The FDA has granted Orphan Drug designation to ARV-1801 (sodium fusidate; Arrevus) for the treatment of pulmonary exacerbations in patients with cystic fibrosis.
Continuous Glucose Monitoring in Youth With Cystic Fibrosis May Detect Early Diabetes
Continuous glucose monitoring may provide a better understanding of the early stages of diabetes progression in youth with cystic fibrosis.
-
Loading...
-
Loading...
Next post in Obstructive Lung Disease
